T Lymphocytic Cell (e.g., T Cell, Thymocyte, Etc.) Patents (Class 424/154.1)
-
Publication number: 20120121503Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: ApplicationFiled: November 12, 2010Publication date: May 17, 2012Applicants: National University Corporation Yamaguchi University, National University Corporation Chiba UniversityInventors: Toshinori Nakayama, Akihiro Hasegawa, Mutsunori Shirai
-
Patent number: 8178098Abstract: Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.Type: GrantFiled: April 3, 2001Date of Patent: May 15, 2012Assignee: National Jewish HealthInventors: Michael F. Lahn, Willi K. Born, Arihiko Kanehiro, Erwin Gelfand
-
Patent number: 8173129Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.Type: GrantFiled: December 7, 2009Date of Patent: May 8, 2012Assignee: The General Hospital CoporationInventor: Denise Faustman
-
Patent number: 8133983Abstract: The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.Type: GrantFiled: March 23, 2009Date of Patent: March 13, 2012Assignee: Crucell Holland B.V.Inventors: Alexander Berthold Hendrik Bakker, Pauline Marie Louise Meester-Rood, Adrianus Quirinus Bakker
-
Patent number: 8124090Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: April 6, 2011Date of Patent: February 28, 2012Assignee: Genentech Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Publication number: 20120045447Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.Type: ApplicationFiled: March 26, 2010Publication date: February 23, 2012Applicant: Bundersrepubik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-InstitutesInventor: Richard Kroczek
-
Patent number: 8110193Abstract: Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for treatment of hematological malignancies and various autoimmune conditions. However, HCT traditionally requires conditioning by total body irradiation and/or chemotherapy, both of which are toxic and induce GVHD. Provided herein are compositions and methods for conditioning a subject for HCT by administering one or more anti-CD3 compounds and one or more histone deacetylase inhibitors. Also provided herein are methods for reducing GVHD in a subject receiving total body irradiation prior to HCT comprising administering one or more anti-CD3 compounds to the subject prior to total body irradiation.Type: GrantFiled: December 18, 2008Date of Patent: February 7, 2012Assignee: City of HopeInventor: Defu Zeng
-
Patent number: 8105830Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: GrantFiled: November 5, 2002Date of Patent: January 31, 2012Assignee: Altor BioScience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
-
Patent number: 8105596Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 15, 2011Date of Patent: January 31, 2012Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 8105599Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: January 31, 2012Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Publication number: 20110318360Abstract: The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-I infection using anti-lipid (e.g. anti-phospholipid) antibodies.Type: ApplicationFiled: September 8, 2009Publication date: December 29, 2011Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, M. Anthony Moody, Bua-Xin Liao
-
Publication number: 20110305700Abstract: The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-1 infection using anti-lipid (e.g. antiphospholipid) antibodies.Type: ApplicationFiled: April 20, 2011Publication date: December 15, 2011Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
-
Publication number: 20110293612Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.Type: ApplicationFiled: December 4, 2009Publication date: December 1, 2011Applicant: ALS Therapy Development InstituteInventors: Steven Perrin, John Monteith Lincecum, Alan Gill, Fernando Vieira
-
Patent number: 8063016Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.Type: GrantFiled: March 31, 2010Date of Patent: November 22, 2011Assignee: Myelos CorporationInventors: David E. Wright, D. Elliot Parks
-
Patent number: 8025883Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.Type: GrantFiled: September 15, 2005Date of Patent: September 27, 2011Assignee: University of Southern CaliforniaInventors: Peter C. Brooks, Jingsong Xu, Eric Petitclerc
-
Patent number: 8012470Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: July 20, 2005Date of Patent: September 6, 2011Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Patent number: 7994289Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: June 18, 2003Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7993641Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: October 16, 2006Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7981416Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.Type: GrantFiled: March 18, 2009Date of Patent: July 19, 2011Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7943135Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: May 17, 2011Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 7939073Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 21, 2005Date of Patent: May 10, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7939076Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).Type: GrantFiled: April 23, 2004Date of Patent: May 10, 2011Assignee: Medarex, Inc.Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
-
Publication number: 20110097337Abstract: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies.Type: ApplicationFiled: August 31, 2007Publication date: April 28, 2011Inventors: Xavier Preville, Benedikt Timmerman
-
Patent number: 7931901Abstract: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described.Type: GrantFiled: August 25, 2006Date of Patent: April 26, 2011Assignees: The Brigham and Women's Hospital, Inc.Inventors: Nalan Utku, Steven R. Gullans, Edgar L. Milford
-
Publication number: 20110091459Abstract: The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 11, 2009Publication date: April 21, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr M. Shahbaz
-
Patent number: 7927596Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: April 19, 2011Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7927595Abstract: Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.Type: GrantFiled: February 20, 1998Date of Patent: April 19, 2011Assignee: The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Richard G. Carroll, James L. Riley, Daniel C. St. Louis, Bruce L. Levine
-
Patent number: 7914790Abstract: A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection.Type: GrantFiled: June 30, 2003Date of Patent: March 29, 2011Inventors: Hidechika Okada, Noriko Okada
-
Patent number: 7914791Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.Type: GrantFiled: May 10, 1999Date of Patent: March 29, 2011Assignee: Trident Pharmaceuticals, Inc.Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
-
Patent number: 7910103Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 1, 2001Date of Patent: March 22, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7901685Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.Type: GrantFiled: October 25, 2005Date of Patent: March 8, 2011Assignee: Progenics Pharmaceuticals Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
-
Publication number: 20110052535Abstract: The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition.Type: ApplicationFiled: April 8, 2009Publication date: March 3, 2011Applicant: TXCELLInventors: Arnaud Foussat, Valerie Brun
-
Patent number: 7892547Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: April 9, 2009Date of Patent: February 22, 2011Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 7892551Abstract: The invention provides a method of enumerating the number of cells of a cell type in a cell sample by (a) counting the white blood cells in the cell sample to obtain the white blood cell population of the sample; (b) determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and (c) calculating the number of cells of the cell type in the sample. The cell type may be a lymphocyte sub-set selected from the group comprising CD4+ lymphocytes, CD 45 cells, CD19 cells, CD16 and CD56 positive cells, CD8 cells, CD3 cells or any combination thereof. The method is particularly useful in monitoring the immune status of a patient infected with HIV or other immune deficiency state or disease or condition where CD4+ lymphocytes or CD4+ T cells are monitored or counted. The invention also provides a kit comprising antibodies necessary for carrying out said cell enumeration.Type: GrantFiled: July 10, 2007Date of Patent: February 22, 2011Assignee: National Health Laboratory ServiceInventor: Deborah Kim Glencross
-
Patent number: 7883703Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.Type: GrantFiled: November 12, 2004Date of Patent: February 8, 2011Assignee: The Brigham and Women's Hospital, Inc.Inventors: Howard L. Weiner, Mohamed H. Sayegh
-
Patent number: 7875279Abstract: The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments.Type: GrantFiled: April 13, 2002Date of Patent: January 25, 2011Assignee: Bioagency AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek
-
Publication number: 20110002934Abstract: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.Type: ApplicationFiled: November 7, 2008Publication date: January 6, 2011Inventors: Mohammad Luqman, Sherna Budhabhatti, Yongyu Wang, Seema Kantak, Ssucheng J. Hsu, Amer M. Mirza
-
Publication number: 20110002939Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1(D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: ApplicationFiled: September 4, 2008Publication date: January 6, 2011Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 7862994Abstract: This invention provides agents determined to be capable of inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+cell and agents determined to be capable of inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+cell. This invention also provides methods to identify such agents. This invention further provides methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+cell susceptible to infection by a T cell-tropic isolate of HIV-1.Type: GrantFiled: July 12, 2001Date of Patent: January 4, 2011Assignee: Progenics Pharmaceuticals Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
-
Patent number: 7837995Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: December 9, 2002Date of Patent: November 23, 2010Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7833530Abstract: The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.Type: GrantFiled: May 15, 2009Date of Patent: November 16, 2010Assignee: Selexys Pharmaceuticals CorporationInventors: Richard Alvarez, Scott Rollins
-
Patent number: 7829092Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: December 18, 2008Date of Patent: November 9, 2010Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 7829096Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: November 9, 2010Assignee: Domantis Ltd.Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7820166Abstract: The present invention relates to a polypeptide construct comprising at least one CDR3 region, wherein at least one of the at least CDR3 regions comprises at least one substitution in the amino acid sequence YYDDHY (SEQ ID NO.1) and wherein the at least one substitution comprises: in the first position of SEQ ID NO.1 a substitution from Y to H; in the second position of SEQ ID NO. 1 a substitution from Y to S, from Y to N, from Y to F or from Y to H; in third position of SEQ ID NO. 1 a substitution from D to N or from D to E; in the forth position of SEQ ID NO. 1 a substitution from D to Q, from D to A, from D to V, from D to E or from D to G; in the fifth position of SEQ ID NO. 1 a substitution from H to Q, from H to P, from H to Y, from H to R or from H to N; or in the sixth position a substitution from Y to N.Type: GrantFiled: October 10, 2003Date of Patent: October 26, 2010Assignee: Micromet AGInventor: Antonio Lanzavecchia
-
Publication number: 20100247430Abstract: The invention provides methods and compositions useful for modulating T cells, and disorders associated with the dysregulation thereof.Type: ApplicationFiled: August 29, 2008Publication date: September 30, 2010Inventors: Andrew Chan, Jung-Hua Yeh
-
Publication number: 20100233183Abstract: The present invention concerns a molecule binding to LAG-3 protein and causing depletion of LAG-3? activated T cells particularly said molecule is a cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof. It also concerns a method of treating or preventing organ transplant rejection or autoimmune diseases in a mammal comprising administering to said mammal a therapeutically effective amount of said antibody.Type: ApplicationFiled: April 30, 2008Publication date: September 16, 2010Inventors: Frederic Triebel, Bernard Vanhove, Thomas Haudebourg
-
Patent number: 7794715Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises particular therapeutic and preventive treatment regimens for the administration of a T-cell immune response cDNA 7 (TIRC7) antagonist, preferably an anti-TIRC7 antibody. Particularly useful monoclonal, in particular chimeric anti-TIRC7 antibodies are described. Furthermore, a combination therapy for the treatment of an inflammatory disease, particularly rheumatoid arthritis, is provided involving the use of TIRC7 antagonist, such as anti-TIRC7 antibody in conjunction with an anti-inflammatory drug such as TNF-? antagonist.Type: GrantFiled: December 23, 2002Date of Patent: September 14, 2010Assignee: CellAct Pharma GmbHInventor: Nalan Utku
-
Patent number: 7790152Abstract: An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active ingredient.Type: GrantFiled: May 2, 2003Date of Patent: September 7, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki Kosaka, Yasuo Koishihara